Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Total Liabilities (2016 - 2025)

Traws Pharma (TRAW) has disclosed Total Liabilities for 14 consecutive years, with $11.2 million as the latest value for Q4 2025.

  • For Q4 2025, Total Liabilities fell 80.13% year-over-year to $11.2 million; the TTM value through Dec 2025 reached $11.2 million, down 80.13%, while the annual FY2025 figure was $11.2 million, 80.13% down from the prior year.
  • Total Liabilities hit $11.2 million in Q4 2025 for Traws Pharma, up from $7.9 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $56.6 million in Q4 2024 and bottomed at $7.4 million in Q2 2025.
  • Average Total Liabilities over 5 years is $13.2 million, with a median of $11.3 million recorded in 2021.
  • Year-over-year, Total Liabilities surged 371.17% in 2024 and then crashed 80.13% in 2025.
  • Traws Pharma's Total Liabilities stood at $9.4 million in 2021, then grew by 18.22% to $11.1 million in 2022, then rose by 8.57% to $12.0 million in 2023, then surged by 371.17% to $56.6 million in 2024, then plummeted by 80.13% to $11.2 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $11.2 million, $7.9 million, and $7.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.